Tags

Type your tag names separated by a space and hit enter

Effects of ChondroT on potassium Oxonate-induced Hyperuricemic mice: downregulation of xanthine oxidase and urate transporter 1.
BMC Complement Altern Med. 2019 Jan 08; 19(1):10.BC

Abstract

BACKGROUND

ChondroT, a new herbal medication, consists of the water extracts of Osterici Radix, Lonicerae Folium, Angelicae Gigantis Radix, Clematidis Radix, and Phellodendri Cortex (6:4:4:4:3). We previously reported that ChondroT showed significant anti-arthritis and anti-inflammatory effects.

METHODS

This study was designed to evaluate the effect of ChondroT on hyperuricemia. First, the effect of ChondroT was evaluated on xanthine oxidase (XOD) activity in vitro. The anti-hyperuricemic effect of ChondroT was also studied in potassium oxonate (PO)-induced hyperuricemic model mice. Uric acid (UA) and XOD were evaluated in the serum, urine, and liver of the mice. In addition, we measured serum creatinine (Cr) and blood urea nitrogen (BUN) levels as well as mRNA expression of the mouse urate transporter 1 (mURAT1) to evaluate kidney function and urate excretion in hyperuricemic mice.

RESULTS

ChondroT showed in vitro XOD inhibitory activity in a dose-dependent manner (P < 0.05). We demonstrated that ChondroT (37.5, 75 and 150 mg/kg) significantly reduced serum UA (P < 0.01 and P < 0.001, respectively), and upregulated urinary UA (P < 0.001, respectively) in PO-induced hyperuricemic mice. In addition, ChondroT (75 and 150 mg/kg) significantly reduced Cr (P < 0.05 and P < 0.01, respectively), BUN (P < 0.05 and P < 0.001, respectively), GOT (P < 0.05 and P < 0.01, respectively), and GPT (P > 0.05 and P < 0.05, respectively) levels in PO-induced hyperuricemic mice. ChondroT (75 and 150 mg/kg) also significantly downregulated serum (P < 0.05) and liver (P < 0.05) XOD activity. Compared to the hyperuricemic mice, the ChondroT (37.5, 75, and 150 mg/kg)-treated mice showed decreased mURAT1 protein expression level.

CONCLUSION

ChondroT displayed anti-hyperuricemic effects by regulating XOD activity and kidney mURAT1.

Authors+Show Affiliations

College of Pharmacy and Research Institute of Drug Development, Chonnam National University, Gwangju, 61186, Republic of Korea. Jeonnam Bioindustry Foundation, Jeollanamdo Institute of Natural Resources Research (JINR), Jeonnam, 59338, Republic of Korea.MEGA BIO Co., Ltd, Jeonnam, 58141, Republic of Korea.Jeonnam Bioindustry Foundation, Jeollanamdo Institute of Natural Resources Research (JINR), Jeonnam, 59338, Republic of Korea.College of Korean Medicine, Dongshin University, 185 Geonjae-ro, Naju-si, Jeollanam-do, 58245, Republic of Korea.College of Korean Medicine, Dongshin University, 185 Geonjae-ro, Naju-si, Jeollanam-do, 58245, Republic of Korea.College of Pharmacy and Research Institute of Drug Development, Chonnam National University, Gwangju, 61186, Republic of Korea.College of Korean Medicine, Dongshin University, 185 Geonjae-ro, Naju-si, Jeollanam-do, 58245, Republic of Korea. mofoster@daum.net. Department of Korean Medicine Rehabilitation, Mokpo Oriental Hospital of Dongshin University, 313 Baengnyeon-daero, Mokpo, 530-822, South Korea. mofoster@daum.net.College of Pharmacy and Research Institute of Drug Development, Chonnam National University, Gwangju, 61186, Republic of Korea. kimyr@chonnam.ac.kr.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

30621705

Citation

Oh, Dool-Ri, et al. "Effects of ChondroT On Potassium Oxonate-induced Hyperuricemic Mice: Downregulation of Xanthine Oxidase and Urate Transporter 1." BMC Complementary and Alternative Medicine, vol. 19, no. 1, 2019, p. 10.
Oh DR, Kim JR, Choi CY, et al. Effects of ChondroT on potassium Oxonate-induced Hyperuricemic mice: downregulation of xanthine oxidase and urate transporter 1. BMC Complement Altern Med. 2019;19(1):10.
Oh, D. R., Kim, J. R., Choi, C. Y., Choi, C. H., Na, C. S., Kang, B. Y., Kim, S. J., & Kim, Y. R. (2019). Effects of ChondroT on potassium Oxonate-induced Hyperuricemic mice: downregulation of xanthine oxidase and urate transporter 1. BMC Complementary and Alternative Medicine, 19(1), 10. https://doi.org/10.1186/s12906-018-2415-2
Oh DR, et al. Effects of ChondroT On Potassium Oxonate-induced Hyperuricemic Mice: Downregulation of Xanthine Oxidase and Urate Transporter 1. BMC Complement Altern Med. 2019 Jan 8;19(1):10. PubMed PMID: 30621705.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effects of ChondroT on potassium Oxonate-induced Hyperuricemic mice: downregulation of xanthine oxidase and urate transporter 1. AU - Oh,Dool-Ri, AU - Kim,Jong Ro, AU - Choi,Chul Yung, AU - Choi,Chan-Hun, AU - Na,Chang-Su, AU - Kang,Bok Yun, AU - Kim,Seon-Jong, AU - Kim,Young Ran, Y1 - 2019/01/08/ PY - 2017/12/01/received PY - 2018/12/19/accepted PY - 2019/1/10/entrez PY - 2019/1/10/pubmed PY - 2019/1/22/medline KW - ChondroT KW - Hyperuricemia KW - URAT1 KW - Uric acid KW - Xanthine oxidase SP - 10 EP - 10 JF - BMC complementary and alternative medicine JO - BMC Complement Altern Med VL - 19 IS - 1 N2 - BACKGROUND: ChondroT, a new herbal medication, consists of the water extracts of Osterici Radix, Lonicerae Folium, Angelicae Gigantis Radix, Clematidis Radix, and Phellodendri Cortex (6:4:4:4:3). We previously reported that ChondroT showed significant anti-arthritis and anti-inflammatory effects. METHODS: This study was designed to evaluate the effect of ChondroT on hyperuricemia. First, the effect of ChondroT was evaluated on xanthine oxidase (XOD) activity in vitro. The anti-hyperuricemic effect of ChondroT was also studied in potassium oxonate (PO)-induced hyperuricemic model mice. Uric acid (UA) and XOD were evaluated in the serum, urine, and liver of the mice. In addition, we measured serum creatinine (Cr) and blood urea nitrogen (BUN) levels as well as mRNA expression of the mouse urate transporter 1 (mURAT1) to evaluate kidney function and urate excretion in hyperuricemic mice. RESULTS: ChondroT showed in vitro XOD inhibitory activity in a dose-dependent manner (P < 0.05). We demonstrated that ChondroT (37.5, 75 and 150 mg/kg) significantly reduced serum UA (P < 0.01 and P < 0.001, respectively), and upregulated urinary UA (P < 0.001, respectively) in PO-induced hyperuricemic mice. In addition, ChondroT (75 and 150 mg/kg) significantly reduced Cr (P < 0.05 and P < 0.01, respectively), BUN (P < 0.05 and P < 0.001, respectively), GOT (P < 0.05 and P < 0.01, respectively), and GPT (P > 0.05 and P < 0.05, respectively) levels in PO-induced hyperuricemic mice. ChondroT (75 and 150 mg/kg) also significantly downregulated serum (P < 0.05) and liver (P < 0.05) XOD activity. Compared to the hyperuricemic mice, the ChondroT (37.5, 75, and 150 mg/kg)-treated mice showed decreased mURAT1 protein expression level. CONCLUSION: ChondroT displayed anti-hyperuricemic effects by regulating XOD activity and kidney mURAT1. SN - 1472-6882 UR - https://www.unboundmedicine.com/medline/citation/30621705/Effects_of_ChondroT_on_potassium_Oxonate_induced_Hyperuricemic_mice:_downregulation_of_xanthine_oxidase_and_urate_transporter_1_ L2 - https://bmccomplementalternmed.biomedcentral.com/articles/10.1186/s12906-018-2415-2 DB - PRIME DP - Unbound Medicine ER -